Skip to main content
Bliss GVS Pharma Limited logo

Bliss GVS Pharma Limited — Investor Relations & Filings

Ticker · BLISSGVS ISIN · INE416D01022 LEI · 335800GXY3YCGGP7KJ45 BSE.NS Manufacturing
Open in API
Filings indexed 1,245 across all filing types
Latest filing 2021-10-22 Regulatory Filings
Country IN India
Listing BSE.NS BLISSGVS

About Bliss GVS Pharma Limited

https://blissgvs.com/

Bliss GVS Pharma Limited specializes in the development, manufacturing, and marketing of diverse pharmaceutical formulations. The company is a global leader in the production of suppositories and pessaries, maintaining an extensive portfolio within these specialized dosage forms. Its therapeutic focus includes anti-malarials, anti-fungals, anti-bacterials, anti-inflammatories, and gastrointestinal treatments. The organization operates state-of-the-art manufacturing facilities compliant with international quality standards, including WHO-GMP. With a strategic focus on emerging markets, the company distributes its range of prescription and over-the-counter products across Sub-Saharan Africa, Southeast Asia, and Latin America, leveraging a robust supply chain to provide accessible healthcare solutions.

Recent filings

Filing Released Lang Actions
Board Meeting — Financial Results
Regulatory Filings Classification · 90% confidence The document is extremely short (328 characters) and contains only an address and stock exchange listing information without any substantive content, financial data, or report details. It appears to be a brief communication or notice to stock exchanges without any report or announcement of voting results, management changes, or financial disclosures. Given the lack of detailed content and the nature of the text, it fits best as a Regulatory Filing (RNS), which is a fallback category for miscellaneous filings that do not fit other specific categories.
2021-10-22 English
BLISS GVS PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/10/2021 ,inter alia, to consider and approve the Unaudited Standalone ....
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges informing about an upcoming Board Meeting scheduled to consider and approve the unaudited financial results for the quarter and half year ended September 30, 2021. It references regulatory compliance under SEBI regulations and mentions the closure of the trading window. The document does not contain any financial data or results itself but is an announcement of a future event related to financial reporting. The document length is short (2501 characters) and it serves as an intimation or notice rather than a report. Therefore, it fits best under the category of Regulatory Filings (RNS) as a general regulatory announcement rather than an Interim Report (IR) or Earnings Release (ER).
2021-10-22 English
Loss of Share Certificates
Regulatory Filings
2021-10-22 English
Pursuant to Regulation 39(3) of Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that Registrar and Share Transfer ....
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges regarding the loss of a share certificate and the issuance of a duplicate share certificate. It references Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to share certificate matters. The content is about informing the exchanges of a shareholder's request for a duplicate share certificate due to loss. This is a notification related to share certificates and does not contain financial data, management discussion, voting results, or other report types. It fits best under the category of Regulatory Filings (RNS) as it is a regulatory compliance announcement that does not fit other specific categories.
2021-10-22 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings Classification · 95% confidence The document is a certificate issued under Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018, confirming securities dematerialization/rematerialization for the quarter ended September 2021. It is a formal attestation letter from a depository participant confirming compliance with regulatory requirements. The document is short (1245 characters) and does not contain any financial statements, analysis, or detailed report data. It is primarily a certification letter rather than a financial report or announcement of a report. According to the Certification Rule, such documents should be classified as Regulatory Filings (RNS).
2021-10-14 English
Please find enclosed herewith a certificate received from Universal Capital Securities Private Limited, Registrar and Share Transfer Agent of the Company under Regulation 74(5) of the Securities ....
Regulatory Filings Classification · 95% confidence The document is a certificate issued under Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018, for the quarter ended September 30, 2021. It is addressed to stock exchanges and confirms dematerialization/rematerialization of securities and compliance with regulatory requirements. The document is short (3598 characters) and primarily serves as a regulatory compliance certificate rather than a financial report or announcement of financial results. It does not contain financial statements or detailed financial data. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for regulatory compliance documents and certificates that do not fit other specific categories.
2021-10-14 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.